Edward Maytin, MD
Dermatology · Cleveland, OHNPI 1376507913
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 56.7% of the total. Reporting peaked in 2023 at $8,239 and has fallen 99.3% since, to $60 in 2025.
Across 15 payments — averaging $966.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$8K
- DUSA Pharmaceuticals, Inc.$6K
- Regeneron Healthcare Solutions, Inc.$71
- Biofrontera Inc.$60
- Amgen$18
Across 9 payments — averaging $19,489 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biofrontera Inc.$143K
- Sun Pharmaceutical Industries Inc.$32K
What the payments were for
- Consulting fees$7,20050%
- Speaking & faculty fees$4,75033%
- Travel & lodging$1,95613%
- Food & beverage$5914%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 8 | $8,220 |
| DUSA Pharmaceuticals, Inc. | 3 | $6,127 |
| Regeneron Healthcare Solutions, Inc. | 1 | $71 |
| Biofrontera Inc. | 2 | $60 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLU-U$8,168
- LEVULAN KERASTICK$6,127
How this compares
$14,497 in reported general payments places this provider in the 85th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Triamcinolone Acetonide | 298 | $905 |
| ValacyclovirValacyclovir Hcl | 35 | $176 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Cleveland
- Neil KormanCleveland$824K
- Shilpi KhetarpalCleveland$383K
- Anthony FernandezCleveland$352K
- Alex HirshCleveland$159K
- Mara Weinstein VelezCleveland$96K
- Samantha PollyCleveland$80K
- Wilma BergfeldCleveland$35K
- David HamrockCleveland$19K
- Matthew ZirwasBexley$3.3M
- George DrewMarion$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.